| Entry |
|
|---|
| Name |
Pemafibrate (JAN);
Parmodia (TN) |
|---|
| Formula |
C28H30N2O6
|
|---|
| Exact mass |
490.2104
|
|---|
| Mol weight |
490.5476
|
|---|
| Structure |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 2183 |
|
|---|
| Efficacy |
Antihyperlipidemic, Triglyceride synthesis inhibitor, Peroxisome proliferator-activated receptor (PPAR) alpha agonist |
|---|
| Target |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C10 LIPID MODIFYING AGENTS
C10A LIPID MODIFYING AGENTS, PLAIN
C10AB Fibrates
C10AB12 Pemafibrate
D10711 Pemafibrate (JAN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
218 Hyperlipidemia agents
2183 Clofibrates
D10711 Pemafibrate (JAN)
Drug groups [BR:br08330]
Hypolipidemic agent
DG01946 Hypolipidemic agent
DG01733 PPAR alpha agonist
DG01547 Fibrate
D10711 Pemafibrate
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
D10711 Pemafibrate
DG01642 CYP2C9 substrate
D10711 Pemafibrate
DG01633 CYP3A/CYP3A4 substrate
D10711 Pemafibrate
Transporter substrate
DG02856 SLCO1B1 substrate
D10711 Pemafibrate
DG02932 SLCO1B3 substrate
D10711 Pemafibrate
Drug classes [BR:br08332]
Cardiovascular agent
DG01946 Hypolipidemic agent
D10711 Pemafibrate
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Thyroid hormone like receptors
Peroxisome proliferator-activated receptor (PPAR)
NR1C1 (PPARA)
D10711 Pemafibrate (JAN) <JP>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10711
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10711
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10711
Drug transporters
D10711
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 36
1 C8x C 4.6200 -17.0100
2 C8x C 4.6200 -18.4100
3 C8x C 5.8324 -19.1100
4 C8y C 7.0449 -18.4100
5 C8y C 7.0449 -17.0100
6 C8x C 5.8324 -16.3100
7 N5x N 8.3764 -18.8426
8 C8y C 9.1993 -17.7100
9 O2x O 8.3764 -16.5774
10 N1c N 10.5700 -17.7100
11 C1b C 11.2700 -18.9224
12 C1b C 11.2700 -16.4976
13 C8y C 12.6698 -16.4976
14 C8x C 13.3797 -17.7268
15 C8x C 14.7797 -17.7266
16 C8x C 15.4796 -16.5141
17 C8y C 14.7697 -15.2849
18 C8x C 13.3697 -15.2851
19 O2a O 15.4806 -14.0537
20 C1c C 16.8699 -14.0539
21 C1b C 17.5631 -12.8536
22 C6a C 17.5768 -15.2785
23 C1a C 18.9698 -12.8538
24 O6a O 18.9699 -15.2785
25 C1b C 12.6698 -18.9224
26 C1b C 13.3603 -20.1180
27 O2a O 14.7697 -20.1180
28 C8y C 15.4577 -21.3095
29 C8x C 14.7735 -22.4945
30 C8x C 15.4735 -23.7069
31 C8y C 16.8735 -23.7069
32 C8x C 17.5577 -22.5219
33 C8x C 16.8577 -21.3094
34 O2a O 17.5828 -24.9350
35 C1a C 18.9699 -24.9346
36 O6a O 16.8830 -16.4798
BOND 39
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 4 7 1
8 7 8 2
9 8 9 1
10 5 9 1
11 8 10 1
12 10 11 1
13 10 12 1
14 12 13 1
15 13 14 2
16 14 15 1
17 15 16 2
18 16 17 1
19 17 18 2
20 13 18 1
21 17 19 1
22 19 20 1
23 20 21 1
24 20 22 1 #Down
25 21 23 1
26 22 24 2
27 11 25 1
28 25 26 1
29 26 27 1
30 27 28 1
31 28 29 2
32 29 30 1
33 30 31 2
34 31 32 1
35 32 33 2
36 28 33 1
37 31 34 1
38 34 35 1
39 22 36 1
|
|---|
